Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer
AssigneeJanssen Pharmaceutica NV
InventorsKazushiro Kawaguchi, Weimin LI, Ryo Oyama, Jaymala Patel, Denis Smirnov
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel biomarkers for detecting resistance and sensitivity to abiraterone acetate-glucocorticoid treatment in a patient having metastatic castration resistant prostate cancer. Also provided are methods of diagnosing and treating abiraterone acetate-glucocorticoid resistant and abiraterone acetate-glucocorticoid sensitive metastatic castration resistant prostate cancer.
Claims21
A method of diagnosing and treating abiraterone acetate-glucocorticoid sensitive metastatic castration resistant prostate cancer in a patient comprising:
- in a patient who has received abiraterone acetate and glucocorticoid treatment, diagnosing the patient as having abiraterone acetate-glucocorticoid sensitive metastatic castration resistant prostate cancer when a level of PSMA, ACADL, NPY, UBE2C, or any combination thereof in a biological sample of the patient is not elevated;
- and
- treating the diagnosed patient with abiraterone acetate and glucocorticoid.
A method of treating metastatic castration resistant prostate cancer in a patient comprising:
- administering abiraterone acetate and glucocorticoid to the patient to treat the metastatic castration resistant prostate cancer, wherein the patient does not have an elevated level of ACADL, NPY, UBE2C, or any combination thereof.
A method of treating metastatic castration resistant prostate cancer in a patient comprising:
- administering abiraterone acetate and glucocorticoid to the patient to treat the metastatic castration resistant prostate cancer, wherein the patient has received abiraterone acetate and glucocorticoid treatment and wherein the patient does not have an elevated level of PSMA, ACADL, NPY, UBE2C, or any combination thereof.
Dependencies are inferred from the claim text.